RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects

Laura Sneller,Christine Lin,Angie Price,Shyam Kottilil,Joel V Chua,Joel V. Chua

DOI: https://doi.org/10.3390/microorganisms12030599

IF: 4.5

2024-03-17

Microorganisms

Abstract:Chronic hepatitis B (CHB) is a global health challenge that can result in significant liver-related morbidity and mortality. Despite a prophylactic vaccine being available, patients already living with CHB often must engage in lifelong therapy with nucleoside analogues. However, the potential of RNA interference (RNAi) therapeutics as a promising avenue for CHB treatment is being explored. RNAi, particularly using small interfering RNA (siRNA), targets viral RNA that can be used to inhibit hepatitis B virus (HBV) replication. Several candidates are currently being studied and have exhibited varying success in reducing hepatitis B surface antigen (HBsAg) levels, with some showing sustained HBsAg loss after cessation of therapy. The dynamic evolution of RNAi therapy presents a promising trajectory for the development of effective and sustained treatments for CHB. This review highlights recent findings on RNAi therapeutics, including modifications for stability, various delivery vectors, and specific candidates currently in development.

microbiology

What problem does this paper attempt to address?

This paper attempts to address the issues in the treatment of chronic hepatitis B (CHB). Although there are currently two treatment methods, nucleos(t)ide analogues (NA) and interferon (IFN), these methods can only suppress viral load and cannot completely cure the disease, with most patients still requiring lifelong treatment. Additionally, the proportion of patients achieving functional cure (i.e., sustained loss of hepatitis B surface antigen HBsAg and suppression of hepatitis B virus HBV DNA) is relatively low.

To address these issues, the paper explores RNA interference (RNAi) therapy as a new approach to treating chronic hepatitis B. RNAi therapy, particularly using small interfering RNA (siRNA), can target viral RNA, thereby inhibiting HBV replication. Studies have shown that some candidate drugs exhibit varying degrees of success in reducing HBsAg levels, with some even maintaining a sustained decline in HBsAg after discontinuation of the drug. The paper reviews the latest advancements in RNAi therapy, including modification methods to enhance stability, various delivery vectors, and specific candidate drugs currently under development. Through these studies, RNAi therapy is expected to become an effective and durable treatment for chronic hepatitis B.